Department of Pediatric Physical Medicine and Rehabilitation, Hospices Civils de Lyon, Bron, France.
National Institute of Nursing Research, National Institutes of Health, Bethesda, MD; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
Arch Phys Med Rehabil. 2021 Apr;102(4):604-610. doi: 10.1016/j.apmr.2020.10.116. Epub 2020 Nov 6.
To investigate the responsiveness of the motor function measure (MFM) and determine the minimal clinically important difference (MCID) in individuals with 2 common types of congenital muscular dystrophy (CMD).
Observational, prospective, single center, cohort study.
National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).
Individuals (N=44) with collagen VI-related dystrophies (COL6-RD, n=23) and 21 individuals laminin alpha2-related muscular dystrophy (LAMA2-RD, n=21) enrolled in a 4-year longitudinal natural history study.
Not applicable.
Responsiveness of the MFM-32 and the Rasch-scaled MFM-25 and the MCID of the MFM-32 determined from a patient-reported anchor with 2 different methods, within-patient and between-patient.
The original MFM-32 and Rasch-scaled MFM-25 performed similarly overall in both the COL6-RD and LAMA2-RD populations, with all subscores (D1, standing and transfers; D2, axial and proximal; D3, distal) showing a significant decrease over time, except MFM D1 and D3 for LAMA2-RD. The MFM D1 subscore was the most sensitive to change for ambulant individuals, whereas the MFM D2 subscore was the most sensitive to change for nonambulant individuals. The MCID for the MFM-32 total score was calculated as 2.5 and 3.9 percentage points according to 2 different methods.
The MFM showed strong responsiveness in individuals with LAMA2-RD and COL6-RD. Because a floor effect was identified more prominently with the Rasch-Scaled MFM-25, the use of the original MFM-32 as a quantitative variable with the assumption of scale linearity appears to be a good compromise. When designing clinical trials in congenital muscular dystrophies, the use of MCID for MFM should be considered to determine if a given intervention effects show not only a statistically significant change but also a clinically meaningful change.
研究运动功能量表(MFM)的反应能力,并确定 2 种常见先天性肌营养不良症(CMD)患者的最小临床重要差异(MCID)。
观察性、前瞻性、单中心队列研究。
美国国立卫生研究院国家神经疾病与卒中研究所(NINDS)。
44 名参与者(23 名胶原 VI 相关营养不良症(COL6-RD)和 21 名层粘连蛋白 alpha2 相关肌营养不良症(LAMA2-RD)患者)参与了一项为期 4 年的纵向自然史研究。
不适用。
MFM-32 和 Rasch 比例化 MFM-25 的反应能力,以及通过患者报告的 2 种不同方法(患者内和患者间)确定的 MFM-32 的 MCID。
原始 MFM-32 和 Rasch 比例化 MFM-25 在 COL6-RD 和 LAMA2-RD 人群中的总体表现相似,所有子量表(D1,站立和转移;D2,轴向和近端;D3,远端)在时间上均有显著下降,除了 LAMA2-RD 的 MFM D1 和 D3。对于能走动的个体,MFM D1 子量表对变化最敏感,而对于不能走动的个体,MFM D2 子量表对变化最敏感。根据 2 种不同方法,MFM-32 总分的 MCID 计算为 2.5 和 3.9 个百分点。
MFM 在 LAMA2-RD 和 COL6-RD 患者中表现出较强的反应能力。由于 Rasch 比例化 MFM-25 更明显地出现了下限效应,因此使用原始 MFM-32 作为具有线性刻度假设的定量变量似乎是一个很好的折衷方案。在设计先天性肌营养不良症的临床试验时,应考虑使用 MCID 进行 MFM,以确定给定的干预措施是否不仅显示出统计学上的显著变化,而且还显示出临床上有意义的变化。